These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 22398092)

  • 1. Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on Crohn's disease: a real-life survey in Spain.
    Hinojosa J; Gisbert JP; Gomollón F; López San Román A
    J Crohns Colitis; 2012 Aug; 6(7):763-70. PubMed ID: 22398092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain.
    Gisbert JP; Gomollón F; Hinojosa J; López San Román A
    J Crohns Colitis; 2010 Nov; 4(5):567-74. PubMed ID: 21122561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concomitant therapy with methotrexate and anti-TNF-α in pediatric patients with refractory crohn's colitis: a case series.
    Absah I; Faubion WA
    Inflamm Bowel Dis; 2012 Aug; 18(8):1488-92. PubMed ID: 21882301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of ulcerative colitis in a real-life setting: An Italian multicenter, prospective, observational AIGO study.
    Scribano ML; Papi C; Costa F; Bortoli A; Bortoluzzi F; Buscarini E; Cappello M; Caserta L; Cortelezzi C; Ferronato A; Manguso F; Mazzuoli S; Orzes N; Kohn A;
    Dig Liver Dis; 2019 Mar; 51(3):346-351. PubMed ID: 30195815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease.
    Ruemmele FM; Veres G; Kolho KL; Griffiths A; Levine A; Escher JC; Amil Dias J; Barabino A; Braegger CP; Bronsky J; Buderus S; Martín-de-Carpi J; De Ridder L; Fagerberg UL; Hugot JP; Kierkus J; Kolacek S; Koletzko S; Lionetti P; Miele E; Navas López VM; Paerregaard A; Russell RK; Serban DE; Shaoul R; Van Rheenen P; Veereman G; Weiss B; Wilson D; Dignass A; Eliakim A; Winter H; Turner D; ;
    J Crohns Colitis; 2014 Oct; 8(10):1179-207. PubMed ID: 24909831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
    J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How thiopurines are used for the treatment of inflammatory bowel diseases: an Italian survey.
    Saibeni S; Kohn A; Meucci G; Papi C;
    Dig Liver Dis; 2015 Feb; 47(2):170-3. PubMed ID: 25467827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study.
    van der Have M; Belderbos TD; Fidder HH; Leenders M; Dijkstra G; Peters CP; Eshuis EJ; Ponsioen CY; Siersema PD; van Oijen MG; Oldenburg B;
    Dig Liver Dis; 2014 Oct; 46(10):881-6. PubMed ID: 25081843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inflammatory bowel diseases (IBD) -- critical discussion of etiology, pathogenesis, diagnostics, and therapy].
    Ochsenkühn T; Sackmann M; Göke B
    Radiologe; 2003 Jan; 43(1):1-8. PubMed ID: 12552369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adalimumab for the treatment of adult Crohn's disease--update of a consensus report by the Working Group Inflammatory Bowel Disease of the Austrian Society of Gastroenterology and Hepatology].
    Novacek G; Haas T; Knoflach P; Petritsch W; Tilg H; Vogelsang H; Reinisch W
    Z Gastroenterol; 2013 Sep; 51(9):1101-9. PubMed ID: 23996653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Infliximab therapy for Crohn's disease - a practical guideline: actualised consensus of the working group for chronic inflammatory bowel diseases of the Austrian Society for Gastroenterology and Hepatology].
    Reinisch W; Dejaco C; Feichtenschlager T; Haas T; Kaser A; Miehsler W; Novacek G; Petritsch W; Platzer R; Tilg H; Vogelsang H; Knoflach P;
    Z Gastroenterol; 2011 Apr; 49(4):534-42. PubMed ID: 21442574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?
    D'Haens GR; Panaccione R; Higgins PD; Vermeire S; Gassull M; Chowers Y; Hanauer SB; Herfarth H; Hommes DW; Kamm M; Löfberg R; Quary A; Sands B; Sood A; Watermeyer G; Lashner B; Lémann M; Plevy S; Reinisch W; Schreiber S; Siegel C; Targan S; Watanabe M; Feagan B; Sandborn WJ; Colombel JF; Travis S
    Am J Gastroenterol; 2011 Feb; 106(2):199-212; quiz 213. PubMed ID: 21045814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biological therapy as treatment of inflammatory bowel diseases].
    Agnholt J
    Ugeskr Laeger; 2008 Jun; 170(24):2152-6. PubMed ID: 18565302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: a real life cohort study.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Crohns Colitis; 2014 Nov; 8(11):1454-63. PubMed ID: 24947334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.
    Dassopoulos T; Sultan S; Falck-Ytter YT; Inadomi JM; Hanauer SB
    Gastroenterology; 2013 Dec; 145(6):1464-78.e1-5. PubMed ID: 24267475
    [No Abstract]   [Full Text] [Related]  

  • 17. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation.
    Arana A; Allen S; Burkowitz J; Fantoni V; Ghatnekar O; Rico MT; Vanhaverbeke N; Wentworth CE; Brosa M; Arellano FM
    Drug Saf; 2010 Jun; 33(6):489-501. PubMed ID: 20486731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.
    Markowitz J; Grancher K; Mandel F; Daum F
    Am J Gastroenterol; 1993 Jan; 88(1):44-8. PubMed ID: 8420272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementing guidelines on the prevention of opportunistic infections in inflammatory bowel disease.
    Walsh AJ; Weltman M; Burger D; Vivekanandarajah S; Connor S; Howlett M; Radford-Smith G; Selby W; Veillard AS; Grimm MC; Travis SP; Lawrance IC
    J Crohns Colitis; 2013 Nov; 7(10):e449-56. PubMed ID: 23601754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A survey of Canadian gastroenterologists about the use of methotrexate in patients with Crohn's disease.
    Chande N; Ponich T; Gregor J
    Can J Gastroenterol; 2005 Sep; 19(9):553-8. PubMed ID: 16151547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.